Tuesday, January 16, 2024 4:58:59 PM
How he may shuffle the deck, including his other Taran entity (the one without control of our product pipeline), and the remaining Humanigen subsidiaries, is anyone's guess. He may look at dedicating the other subsidiaries to specific medical fields, because I see wide open spaces to focus on beyond covid and oncology, as I recently noted in regards to MS and malaria, and then look to enter into further partnerships to advance those opportunities.
In addition, we have long-standing partnership interests in fields such as arthritis and asthma, which are mature markets, but they are large, and as it does, lenz will possibly revolutionize the treatment of those indications, giving us huge opportunity in these developed areas.
I am not only entirely comfortable with this investment, I am excited to see how much more value Durrant and Dale will bring to Humanigen's shareholders.
Thank you for the question.
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM